Median affordability (days’ wages) of insulin and comparator medicines across countries
| Public sector | Private retail pharmacies | Private hospitals/clinics | ||||
| Median days’ wages (range) | N | Median days’ wages (range) | N | Median days’ wages (range) | N | |
| Insulins (10 mL 100 IU/mL) | ||||||
| Short-acting human | 3.9 (0.3–6.8) | 9 | 3.7 (1.2 to 20.2) | 14 | 4.2 (0.7–21.7) | 12 |
| Intermediate-acting human | 3.6 (1.6–4.8) | 6 | 4.3 (1.3 to 30.4) | 13 | 5.0 (0.5–21.7) | 12 |
| Mixed human | 3.5 (0.5–6.5) | 8 | 2.2 (1.2 to 7.5) | 13 | 3.7 (1.3–22.1) | 11 |
| Rapid-acting analogue | 6.3 (4.9–7.4) | 4 | 6.6 (2.7 to 50.9) | 13 | 6.8 (3.1–14.0) | 6 |
| Long-acting analogue | 7.9 (4.5–17.3) | 5 | 15.6 (4.6 to 94.2) | 15 | 14.3 (4.5–43.1) | 9 |
| Mixed analogue | 6.1 (2.8–8.8) | 6 | 7.9 (3.2 to 43.5) | 14 | 6.7 (3.3–14.0) | 8 |
| Comparator medicines | ||||||
| Metformin 500 mg ×90 | HP: 2.4 (0.1–5.2) | 9 | HP: 2.2 (0.3 to 13.4) | 15 | HP: 2.0 (0.3–7.2) | 13 |
| LP: 1.3 (0.1–5.2) | LP: 0.8 (0.2 to 11.2) | LP: 1.2 (0.3–4.3) | ||||
| Gliclazide 80 mg ×30 | HP: 0.6 (0.3–2.2) | 4 | HP: 0.7 (0.5 to 2.6) | 8 | HP and LP: 1.0 (0.5–3.4) | 9 |
| LP: 0.4 (0.2–0.7) | LP: 0.5 (0.2 to 2.6) | |||||
| Enalapril 10 mg ×30 | HP: 0.6 (0.2–0.9) | 5 | HP: 0.8 (0.3 to 4.4) | 14 | HP: 1.0 (0.1–6.1) | 12 |
| LP: 0.5 (0.1–0.9) | LP: 0.7 (0.2 to 4.4) | LP: 0.8 (0.1–6.1) | ||||
| Ceftriaxone 1 g vial ×1 | HP: 1.2 (0.1–3.6) | 8 | HP: 2.3 (0.1 to 8.7) | 14 | HP: 1.1 (0.1–5.1) | 14 |
| LP: 0.5 (0.1–1.5) | LP: 0.4 (0.1 to 0.9) | LP: 0.6 (0.1–2.8) | ||||
HP, highest priced products; LP, lowest priced products; N, number of surveys.